Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

Journal of Medical Virology

Volumn 80, Issue 10, 2008, Pages 1695-1706

  Saracino, Annalisa ^a   Gianotti, Nicola ^b   Marangi, Marianna ^a   Cibelli, Donatella C ^a   Galli, Andrea ^b   Punzi, Grazia ^c   Monno, Laura ^c   Lazzarin, Adriano ^b   Angarano, Gioacchino ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Antiretroviral genotypic resistance; HAART failure; HIV 1; Plasma RNA; Proviral DNA

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; DNA POLYMERASE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; FOLLOW UP; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; TREATMENT DURATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MULTICENTER STUDIES AS TOPIC; MUTATION; PROVIRUSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 50849143192     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21261     Document Type: Article

References (29)

1. Bertagnolio S, Soto-Ramirez L, Pilon R, Rodriguez R, Viveros M, Fuentes L, Harrigan PR, Mo T, Sutherland D, Sandstrom P. 2007. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 12:107-113.
2. Bi X, Gatanaga H, Ida S, Tsuchiya K, Matsuoka-Aizawa S, Kimura S, Oka S. 2003. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 34:1-6.
3. Bon I, Gibellini D, Borderi M, Alessandrini F, Vitone F, Schiavone P, Re MC. 2007. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 38:313-320.
4. Booth CL, Geretti AM. 2007. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59:1047-1056.
5. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, Saksena NK. 2005. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 33:206-216.
6. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A, Johnson M. 2000. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses 16:1025-1030.
7. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008. 1-128. Available at http://AIDSinfo.nih.gov.
8. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
9. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517.
10. Gianotti N, Mondino V, Rossi MC, Chiesa E, Mezzaroma I, Ladisa N, Guaraldi G, Torti C, Tarquini P, Castelli P, Di Carlo A, Boeri E, Keulen W, Mc Kenna P, Lazzarin A, on behalf of the Mutations and Salvage (MuSa) Study Group. 2006. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV infected patients by a randomized clinical trial: The mutations and salvage study. Clin Infect Dis 42:1470-1480.
11. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15:119-125.
12. Kaye S, Comber E, Tenant-Flowers M, Loveday C. 1995. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses 11:1221-1225.
13. Keiser P. 2002. Role of sequencing in therapy selection. Review. J Acquir Immune Defic Syndr 29:S19-S27.
14. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, Ussery M, Kalish ML, Heneine W, Garcia-Lerma JG. 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45:517-521.
15. Monno L, Punzi G, Scarabaggio T, Saracino A, Brindicci G, Fiore JR, Iambrenghi OC, Di Stefano M, Pastore G, Angarano G. 2003. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. J Med Virol 70:1-9.
16. Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L, Gerna G. 2001. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 65:207-217.
17. Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palù G. 2007. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol 45:1783-1788.
18. Potter SJ, Dwyer DE, Saksena NK. 2003. Differential cellular distribution of HIV-1 drug resistance in vivo: Evidence for Infection of CD8_ T Cells during HAART. Virology 305:339-352.
19. Punzi G, Saracino A, Brindicci G, Scarabaggio T, Lagioia A, Angarano G, Monno L. 2005. HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic. J Med Virol 77:457-459.
20. Sarmati L, Nicastri E, Uccella I, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Concia E, Vullo V, Vella S, Andreoni M. 2003. Drug-associated mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 41:1760-1762.
21. Steegen K, Luchters S, Demecheleer E, Dauwe K, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C. 2007. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol 45:3342-3351.
22. Turriziani O, Bucci M, Stano A, Scagnolari C, Bellomi F, Fimiani C, Mezzaroma I, D'Ettorre G, Brogi A, Vullo V, Antonelli G. 2007. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 44:518-524.
23. Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. 2004. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 9:829-848.
24. Venturi G, Romano L, Carli T, Corsi P, Pippi L, Valensin PE, Zazzi M. 2002. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir Ther 7:245-250.
25. Vicenti I, Razzolini F, Saladini F, Romano L, Zazzi M. 2007. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis 44:1657-1661.
26. Wang YM, Dyer WB, Workman C, Wang B, Sullivan JS, Saksena NK. 2000. Molecular evidence for druginduced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. AIDS 14:2265-2272.
27. Wang YM, Dyer WB, Workman C, Wang B, Peng NK, Lachireddy K, Chew CB, Sullivan J, Saksena NK. 2007. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 5:235-250.
28. Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA, SPREAD Programme. 2005, Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 192:958-966.
29. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, Antinori A. Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. 2005. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 19:1081-1089.